Canagliflozin (Invokana) for the treatment of adults with 'type 2 diabetes mellitus'
The WAR has approved a pharmacotherapeutic report for the medicine canagliflozin (Invokana) in film-coated tablets with 100 mg/300 mg active ingredient. In determining its therapeutic value, add-on therapy in a two-fold combination with metformin was compared with the addition of an SU-derivative, sitagliptin, dapagliflozin or pioglitazone to metformin. They reached the following conclusion.
- the therapeutic value of canagliflozin in combination with metformin for the treatment of type 2 diabetes mellitus is equivalent to that of an SU-derivative, DPP-4 inhibitors, dapagliflozin or pioglitazone.